rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2025-229-238rsp-3762Research ArticleМЕЖДУНАРОДНЫЕ И РОССИЙСКИЕ РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЙINTERNATIONAL AND RUSSIAN GUIDELINES FOR THE TREATMENT OF RHEUMATIC DISEASES10 лет стратегии лечения системной красной волчанки «до достижения цели» (treat-to-target SLE). Обсуждение текущих ограничений и доступные варианты ее внедрения в реальную клиническую практикуTreat-to-target SLE strategy in 10 years: Discussion of current limitations and available options for implementation in real-world clinical practicehttps://orcid.org/0000-0002-1663-7810АсееваЕ. А.AseevaE. A.

Асеева Елена Александровна.

115522, Москва, Каширское шоссе, 34а

Elena A. Aseeva.

115522, Moscow, Kashirskoye Highway, 34A

eaasseeva@mail.ruhttps://orcid.org/0000-0002-5206-1732СоловьевС. К.SolovyevS. K.

115522, Москва, Каширское шоссе, 34а

Sergey K. Solovyev.

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0009-0005-1269-5799ПлетневЕ. А.PletnevE. A.

115522, Москва, Каширское шоссе, 34а

Evgenii A. Pletnev.

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-5433-3300КойлубаеваГ. М.KoilubaevaG. M.

720040, Бишкек, ул. Тоголок Молдо, 3

Gulazik M. Koilubaeva.

720040, Bishkek, Togoloka Moldo str., 3

https://orcid.org/0000-0002-4630-3985ИсаеваБ. Г.IssayevaB. G.

050012, Алматы, ул. Толе би, 94

Bakytsholpan G. Issayeva.

050012, Almaty, Tole bi str., 94

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а

Evgeny L. Nasonov.

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationНациональный центр кардиологии и терапии имени академика Мирсаида Миррахимова при Министерстве здравоохранения Кыргызской РеспубликиКыргызстанNational Center for Cardiology and Therapy named after Academician Mirsaid Mirrahimov of the Ministry of Health of the Kyrgyz RepublicKyrgyzstanНАО «Казахский национальный медицинский университет имени С.Д. Асфендиярова»КазахстанKazakh National Medical University named after S.D. AsfendiyarovKazakhstan202502072025633229238Copyright © Асеева Е.А., Соловьев С.К., Плетнев Е.А., Койлубаева Г.М., Исаева Б.Г., Насонов Е.Л., 20252025Асеева Е.А., Соловьев С.К., Плетнев Е.А., Койлубаева Г.М., Исаева Б.Г., Насонов Е.Л.Aseeva E.A., Solovyev S.K., Pletnev E.A., Koilubaeva G.M., Issayeva B.G., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3762

В январе 2013 г. по инициативе ведущих мировых ревматологов R.F. van Vollenhoven, J. Smolen, M. Mosca и M. Schneider стартовал проект создания концепции «Лечение до достижения цели» для системной красной волчанки (СКВ). В 2014 г. были опубликованы подготовленные этой группой рекомендации «Лечение СКВ до достижения цели». В статье обсуждаются проблемы внедрения стратегии в реальную клиническую практику и обсуждаются предполагаемые пути ее реализации, предложенные международными экспертами в 2025 г.: 5 основных принципов и 11 утверждений.

In January 2013, at the initiative of the world’s leading rheumatologists Ronald F. van Vollenhoven, Josef Smolen, Marta Mosca and Matthias Schneider, a project was launched to create the “Treat-to-Target” concept for systemic lupus erythematosus (SLE). In 2014, the group published recommendations “Treat-to-Target for SLE”. The article discusses the problems of implementing the strategy in real clinical practice and discusses the proposed ways of its implementation, proposed by international experts in 2025: 5 basic principles and 11 statements.

стратегия «лечение до достижения цели»СКВТ2ТTreat-to-Target SLEТ2ТSLEReferencesНасонов ЕЛ, Соловьев СК, Аршинов АВ. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412. doi: 10.47360/1995-4484-2022-397-412Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: History and modernity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):397-412 (In Russ.). doi: 10.47360/1995-4484-2022-397-412van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi: 10.1136/annrheumdis-2013-205139van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi: 10.1136/annrheumdis-2013-205139Соловьев СК, Асеева ЕА, Попкова ТВ Клюквина НГ, Решетняк ТМ, Лисицына ТА, и др. Стратегия лечения системной красной волчанки «до достижения цели» (Treat-to-Target SLE). Pекомендации международной рабочей группы и комментарии российских экспертов. Научно-практическая ревматология. 2015;53(1):9-16. doi: 10.14412/1995-4484-2015-9-16Soloviev SK, Aseeva EA, Popkova TV, Klyukvina NG, Reshetnyak TM, Lisitsyna TA, et al. Treat-to-target SLE recommendations from the international task force and Russian experts’ commentaries. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2015;53(1):9-16 (In Russ.). doi: 10.14412/1995-4484-2015-9-16Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762Franklyn K, Hoi A, Nikpour M, Morand EF. The need to define treatment goals for systemic lupus erythematosus. Nat Rev Rheumatol. 2014;10(9):567-571. doi: 10.1038/nrrheum.2014.118Franklyn K, Hoi A, Nikpour M, Morand EF. The need to define treatment goals for systemic lupus erythematosus. Nat Rev Rheumatol. 2014;10(9):567-571. doi: 10.1038/nrrheum.2014.118Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, et al.; Asia-Pacific Lupus Collaboration. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75(9):1615-1621. doi: 10.1136/annrheumdis-2015-207726Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, et al.; Asia-Pacific Lupus Collaboration. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75(9):1615-1621. doi: 10.1136/annrheumdis-2015-207726Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.Urowitz MB, Feletar M, Bruce IN, Ibañez D, Gladman DD. Prolonged remission in systemic lupus erythematosus. J Rheumatol. 2005;32(8):1467-1472.Urowitz MB, Feletar M, Bruce IN, Ibañez D, Gladman DD. Prolonged remission in systemic lupus erythematosus. J Rheumatol. 2005;32(8):1467-1472.van Vollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA, et al. 2021 DORIS definition of remission in SLE: Final recommendations from an international task force. Lupus Sci Med. 2021;8(1):e000538. doi: 10.1136/lupus-2021-000538van Vollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA, et al. 2021 DORIS definition of remission in SLE: Final recommendations from an international task force. Lupus Sci Med. 2021;8(1):e000538. doi: 10.1136/lupus-2021-000538Zucchi D, Cardelli C, Elefante E, Tani C, Mosca M. Treat-to-target in systemic lupus erythematosus: Reality or pipe dream. J Clin Med. 2023;12(9):3348. doi: 10.3390/jcm12093348Zucchi D, Cardelli C, Elefante E, Tani C, Mosca M. Treat-to-target in systemic lupus erythematosus: Reality or pipe dream. J Clin Med. 2023;12(9):3348. doi: 10.3390/jcm12093348Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43:1801-1808.Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43:1801-1808.Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30(9):1955-1959.Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30(9):1955-1959.Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol. 2012;176:708-719. doi: 10.1093/aje/kws130Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol. 2012;176:708-719. doi: 10.1093/aje/kws130Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(4):R109. doi: 10.1186/ar2764Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(4):R109. doi: 10.1186/ar2764Murimi-Worstell IB, Lin DH, Nab H, Kan HJ, Onasanya O, Tierce JC, et al. Association between organ damage and mortality in systemic lupus erythematosus: A systematic review and meta-analysis. BMJ Open. 2020;10(5):e031850. doi: 10.1136/bmjo-pen-2019-031850Murimi-Worstell IB, Lin DH, Nab H, Kan HJ, Onasanya O, Tierce JC, et al. Association between organ damage and mortality in systemic lupus erythematosus: A systematic review and meta-analysis. BMJ Open. 2020;10(5):e031850. doi: 10.1136/bmjo-pen-2019-031850Zahr ZA, Fang H, Magder LS, Petri M. Predictors of corticosteroid tapering in SLE patients: The Hopkins Lupus Cohort. Lupus. 2013;22(7):697-701. doi: 10.1177/0961203313490434Zahr ZA, Fang H, Magder LS, Petri M. Predictors of corticosteroid tapering in SLE patients: The Hopkins Lupus Cohort. Lupus. 2013;22(7):697-701. doi: 10.1177/0961203313490434Mathian A, Pha M, Haroche J, Cohen-Aubart F, Hié M, Pineton de Chambrun M, et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: A randomised clinical trial. Ann Rheum Dis. 2020;79(3):339-346. doi: 10.1136/annrheumdis-2019-216303Mathian A, Pha M, Haroche J, Cohen-Aubart F, Hié M, Pineton de Chambrun M, et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: A randomised clinical trial. Ann Rheum Dis. 2020;79(3):339-346. doi: 10.1136/annrheumdis-2019-216303Tselios K, Gladman DD, Su J, Urowitz MB. Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus. ACR Open Rheumatol. 2021;3(8):550-557. doi: 10.1002/acr2.11267Tselios K, Gladman DD, Su J, Urowitz MB. Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus. ACR Open Rheumatol. 2021;3(8):550-557. doi: 10.1002/acr2.11267Tani C, Elefante E, Signorini V, Zucchi D, Lorenzoni V, Carli L, et al. Glucocorticoid withdrawal in systemic lupus erythematosus: Are remission and low disease activity reliable starting points for stopping treatment? A real-life experience. RMD Open. 2019;5(2):e000916. doi: 10.1136/rmdopen-2019-000916Tani C, Elefante E, Signorini V, Zucchi D, Lorenzoni V, Carli L, et al. Glucocorticoid withdrawal in systemic lupus erythematosus: Are remission and low disease activity reliable starting points for stopping treatment? A real-life experience. RMD Open. 2019;5(2):e000916. doi: 10.1136/rmdopen-2019-000916Nakai T, Fukui S, Ikeda Y, Suda M, Tamaki H, Okada M. Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: A single-center retrospective analysis. Lupus Sci Med. 2022;9(1):e000682. doi: 10.1136/lupus-2022-000682Nakai T, Fukui S, Ikeda Y, Suda M, Tamaki H, Okada M. Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: A single-center retrospective analysis. Lupus Sci Med. 2022;9(1):e000682. doi: 10.1136/lupus-2022-000682Goswami RP, Sit H, Ghosh P, Sircar G, Ghosh A. Steroid-free remission in lupus: Myth or reality; an observational study from a tertiary referral centre. Clin Rheumatol. 2019;38(4):1089-1097. doi: 10.1007/s10067-018-4377-7Goswami RP, Sit H, Ghosh P, Sircar G, Ghosh A. Steroid-free remission in lupus: Myth or reality; an observational study from a tertiary referral centre. Clin Rheumatol. 2019;38(4):1089-1097. doi: 10.1007/s10067-018-4377-7Piga M, Parodis I, Touma Z, Legge A, Ugarte-Gil MF, Hmamouchi I, et al. Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: Consensus statements from an international task force. Autoimmun Rev. 2025;24(5):103773. doi: 10.1016/j.autrev.2025.103773Piga M, Parodis I, Touma Z, Legge A, Ugarte-Gil MF, Hmamouchi I, et al. Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: Consensus statements from an international task force. Autoimmun Rev. 2025;24(5):103773. doi: 10.1016/j.autrev.2025.103773Piga M, Floris A, Sebastiani GD, Prevete I, Iannone F, Coladonato L, et al. Risk factors of damage in early diagnosed systemic lupus erythematosus: Results of the Italian multicentre Early Lupus Project inception cohort. Rheumatology (Oxford). 2020;59(9):2272-2281. doi: 10.1093/rheumatology/kez584Piga M, Floris A, Sebastiani GD, Prevete I, Iannone F, Coladonato L, et al. Risk factors of damage in early diagnosed systemic lupus erythematosus: Results of the Italian multicentre Early Lupus Project inception cohort. Rheumatology (Oxford). 2020;59(9):2272-2281. doi: 10.1093/rheumatology/kez584Piga M, Floris A, Cappellazzo G, Chessa E, Congia M, Mathieu A, et al. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis Res Ther. 2017;19(1):247. doi: 10.1186/s13075-017-1451-5Piga M, Floris A, Cappellazzo G, Chessa E, Congia M, Mathieu A, et al. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis Res Ther. 2017;19(1):247. doi: 10.1186/s13075-017-1451-5Zen M, Gatto M, Doria A. Defining the targets in SLE management: Insights and unmet gaps. Ann Rheum Dis. 2022;81(11):1483-1485. doi: 10.1136/ard-2022-222991Zen M, Gatto M, Doria A. Defining the targets in SLE management: Insights and unmet gaps. Ann Rheum Dis. 2022;81(11):1483-1485. doi: 10.1136/ard-2022-222991Mendoza-Pinto C, Etchegaray-Morales I, Ugarte-Gil MF. Improving access to SLE therapies in low and middle-income countries. Rheumatology (Oxford). 2023;62(Suppl 1):30-35. doi: 10.1093/rheumatology/keac530Mendoza-Pinto C, Etchegaray-Morales I, Ugarte-Gil MF. Improving access to SLE therapies in low and middle-income countries. Rheumatology (Oxford). 2023;62(Suppl 1):30-35. doi: 10.1093/rheumatology/keac530Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: What does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44(5):681-692. doi: 10.1016/s0277-9536(96)00221-3Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: What does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44(5):681-692. doi: 10.1016/s0277-9536(96)00221-3Cai T, Zhao J, Yang Y, Jiang Y, Zhang JA. Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies. Lupus. 2022;31(14):1714-1725. doi: 10.1177/09612033221129774Cai T, Zhao J, Yang Y, Jiang Y, Zhang JA. Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies. Lupus. 2022;31(14):1714-1725. doi: 10.1177/09612033221129774Pagès-Puigdemont N, Mangues MA, Masip M, Gabriele G, Fernández-Maldonado L, Blancafort S, et al. Patients’ perspective of medication adherence in chronic conditions: A qualitative study. Adv Ther. 2016;33(10):1740-1754. doi: 10.1007/s12325-016-0394-6Pagès-Puigdemont N, Mangues MA, Masip M, Gabriele G, Fernández-Maldonado L, Blancafort S, et al. Patients’ perspective of medication adherence in chronic conditions: A qualitative study. Adv Ther. 2016;33(10):1740-1754. doi: 10.1007/s12325-016-0394-6Parodis I, Girard-Guyonvarc’h C, Arnaud L, Distler O, Domján A, Van den Ende CHM, et al. EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. Ann Rheum Dis. 2024;83(6):720-729. doi: 10.1136/ard-2023-224416Parodis I, Girard-Guyonvarc’h C, Arnaud L, Distler O, Domján A, Van den Ende CHM, et al. EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. Ann Rheum Dis. 2024;83(6):720-729. doi: 10.1136/ard-2023-224416So H, Szeto CC, Tam LS. Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak. Ann Rheum Dis. 2021;80(6):e97. doi: 10.1136/annrheumdis-2020-218220So H, Szeto CC, Tam LS. Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak. Ann Rheum Dis. 2021;80(6):e97. doi: 10.1136/annrheumdis-2020-218220Au Eong JTW, Lateef A, Liang S, Lim SHH, Tay SH, Mak A, et al. Impact of teleconsultation on subsequent disease activity and flares in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022;61(5):1911-1918. doi: 10.1093/rheumatology/keab694Au Eong JTW, Lateef A, Liang S, Lim SHH, Tay SH, Mak A, et al. Impact of teleconsultation on subsequent disease activity and flares in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022;61(5):1911-1918. doi: 10.1093/rheumatology/keab694Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, et al.; Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR). First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis. 2018;77(11):1549-1557. doi: 10.1136/annrheumdis-2018-213512Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, et al.; Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR). First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis. 2018;77(11):1549-1557. doi: 10.1136/annrheumdis-2018-213512Kandane-Rathnayake R, Golder V, Louthrenoo W, Chen YH, Cho J, Lateef A, et al.; Asia-Pacific Lupus Collaboration. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: A prospective, multinational, longitudinal cohort study. Lancet Rheumatol. 2022;4(12):e822-e830. doi: 10.1016/S2665-9913(22)00304-6Kandane-Rathnayake R, Golder V, Louthrenoo W, Chen YH, Cho J, Lateef A, et al.; Asia-Pacific Lupus Collaboration. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: A prospective, multinational, longitudinal cohort study. Lancet Rheumatol. 2022;4(12):e822-e830. doi: 10.1016/S2665-9913(22)00304-6Golder V, Kandane-Rathnayake R, Huq M, Nim HT, Louthrenoo W, Luo SF, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: A prospective validation study. Lancet Rheumatol. 2019;1(2):e95-e102. doi: 10.1016/S2665-9913(19)30037-2Golder V, Kandane-Rathnayake R, Huq M, Nim HT, Louthrenoo W, Luo SF, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: A prospective validation study. Lancet Rheumatol. 2019;1(2):e95-e102. doi: 10.1016/S2665-9913(19)30037-2Zen M, Iaccarino L, Gatto M, Bettio S, Nalotto L, Ghirardello A, et al. Prolonged remission in Caucasian patients with SLE: Prevalence and outcomes. Ann Rheum Dis. 2015;74(12):2117-2122. doi: 10.1136/annrheumdis-2015-207347Zen M, Iaccarino L, Gatto M, Bettio S, Nalotto L, Ghirardello A, et al. Prolonged remission in Caucasian patients with SLE: Prevalence and outcomes. Ann Rheum Dis. 2015;74(12):2117-2122. doi: 10.1136/annrheumdis-2015-207347Yang Z, Cheng C, Wang Z, Wang Y, Zhao J, Wang Q, et al. Prevalence, predictors, and prognostic benefits of remission achievement in patients with systemic lupus erythematosus: A systematic review. Arthritis Care Res (Hoboken). 2022;74(2):208-218. doi: 10.1002/acr.24464Yang Z, Cheng C, Wang Z, Wang Y, Zhao J, Wang Q, et al. Prevalence, predictors, and prognostic benefits of remission achievement in patients with systemic lupus erythematosus: A systematic review. Arthritis Care Res (Hoboken). 2022;74(2):208-218. doi: 10.1002/acr.24464Floris A, Piga M, Perra D, Chessa E, Congia M, Mathieu A, et al. Treatment target in newly diagnosed systemic lupus erythematosus: The association of lupus low disease activity state and remission with lower accrual of early damage. Arthritis Care Res (Hoboken). 2020;72(12):1794-1799. doi: 10.1002/acr.24086Floris A, Piga M, Perra D, Chessa E, Congia M, Mathieu A, et al. Treatment target in newly diagnosed systemic lupus erythematosus: The association of lupus low disease activity state and remission with lower accrual of early damage. Arthritis Care Res (Hoboken). 2020;72(12):1794-1799. doi: 10.1002/acr.24086Moroni G, Gatto M, Tamborini F, Quaglini S, Radice F, Saccon F, et al. Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis. 2020;79(8):1077-1083. doi: 10.1136/annrheumdis-2020-216965Moroni G, Gatto M, Tamborini F, Quaglini S, Radice F, Saccon F, et al. Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis. 2020;79(8):1077-1083. doi: 10.1136/annrheumdis-2020-216965Gatto M, Frontini G, Calatroni M, Reggiani F, Depascale R, Cruciani C, et al. Effect of sustained clinical remission on the risk of lupus flares and impaired kidney function in patients with lupus nephritis. Kidney Int Rep. 2024;9(4):1047-1056. doi: 10.1016/j.ekir.2024.01.016Gatto M, Frontini G, Calatroni M, Reggiani F, Depascale R, Cruciani C, et al. Effect of sustained clinical remission on the risk of lupus flares and impaired kidney function in patients with lupus nephritis. Kidney Int Rep. 2024;9(4):1047-1056. doi: 10.1016/j.ekir.2024.01.016Chambers SA, Rahman A, Isenberg DA. Treatment adherence and clinical outcome in systemic lupus erythematosus. Rheumatology (Oxford). 2007;46:895-898.Chambers SA, Rahman A, Isenberg DA. Treatment adherence and clinical outcome in systemic lupus erythematosus. Rheumatology (Oxford). 2007;46:895-898.Nguyen Y, Blanchet B, Urowitz MB, Hanly JG, Gordon C, Bae SC, et al. Association between severe nonadherence to hydroxychloroquine and systemic lupus erythematosus flares, damage, and mortality in 660 patients from the SLICC inception cohort. Arthritis Rheumatol. 2023;75(12):2195-2206. doi: 10.1002/art.42645Nguyen Y, Blanchet B, Urowitz MB, Hanly JG, Gordon C, Bae SC, et al. Association between severe nonadherence to hydroxychloroquine and systemic lupus erythematosus flares, damage, and mortality in 660 patients from the SLICC inception cohort. Arthritis Rheumatol. 2023;75(12):2195-2206. doi: 10.1002/art.42645Dall’Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2011;63(3):351-357. doi: 10.1002/acr.20397Dall’Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2011;63(3):351-357. doi: 10.1002/acr.20397Tamirou F, Lauwerys BR, Dall’Era M, Mackay M, Rovin B, Cervera R, et al.; MAINTAIN Nephritis Trial Investigators. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: Data from the MAINTAIN Nephritis Trial. Lupus Sci Med. 2015;2(1):e000123. doi: 10.1136/lupus-2015-000123Tamirou F, Lauwerys BR, Dall’Era M, Mackay M, Rovin B, Cervera R, et al.; MAINTAIN Nephritis Trial Investigators. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: Data from the MAINTAIN Nephritis Trial. Lupus Sci Med. 2015;2(1):e000123. doi: 10.1136/lupus-2015-000123Parodis I, Adamichou C, Aydin S, Gomez A, Demoulin N, Weinmann-Menke J, et al. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology (Oxford). 2020;59(11):3424-3434. doi: 10.1093/rheumatology/keaa129Parodis I, Adamichou C, Aydin S, Gomez A, Demoulin N, Weinmann-Menke J, et al. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology (Oxford). 2020;59(11):3424-3434. doi: 10.1093/rheumatology/keaa129Cruciani C, Zen M, Gatto M, Morand E, Doria A. Assessment of disease activity and damage in SLE: Are we there yet? Best Pract Res Clin Rheumatol. 2023;37(4):101896. doi: 10.1016/j.berh.2023.101896Cruciani C, Zen M, Gatto M, Morand E, Doria A. Assessment of disease activity and damage in SLE: Are we there yet? Best Pract Res Clin Rheumatol. 2023;37(4):101896. doi: 10.1016/j.berh.2023.101896Zen M, Iaccarino L, Gatto M, Bettio S, Saccon F, Ghirardello A, et al. The effect of different durations of remission on damage accrual: Results from a prospective monocentric cohort of Caucasian patients. Ann Rheum Dis. 2017;76(3):562-565. doi: 10.1136/annrheumdis-2016-210154Zen M, Iaccarino L, Gatto M, Bettio S, Saccon F, Ghirardello A, et al. The effect of different durations of remission on damage accrual: Results from a prospective monocentric cohort of Caucasian patients. Ann Rheum Dis. 2017;76(3):562-565. doi: 10.1136/annrheumdis-2016-210154Zen M, Salmaso L, Barbiellini Amidei C, Fedeli U, Bellio S, Iaccarino L, et al. Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study. Eur J Intern Med. 2023;112:45-51. doi: 10.1016/j.ejim.2023.02.004Zen M, Salmaso L, Barbiellini Amidei C, Fedeli U, Bellio S, Iaccarino L, et al. Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study. Eur J Intern Med. 2023;112:45-51. doi: 10.1016/j.ejim.2023.02.004Ugarte-Gil MF, Mendoza-Pinto C, Reátegui-Sokolova C, Pons-Estel GJ, van Vollenhoven RF, Bertsias G, et al. Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: A systematic literature review. Lupus Sci Med. 2021;8(1):e000542. doi: 10.1136/lupus-2021-000542Ugarte-Gil MF, Mendoza-Pinto C, Reátegui-Sokolova C, Pons-Estel GJ, van Vollenhoven RF, Bertsias G, et al. Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: A systematic literature review. Lupus Sci Med. 2021;8(1):e000542. doi: 10.1136/lupus-2021-000542Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int. 2024;105(1S):1-69. doi: 10.1016/j.kint.2023.09.002Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int. 2024;105(1S):1-69. doi: 10.1016/j.kint.2023.09.002Sammaritano LR, Askanase A, Bermas BL, Dall’Era M, Duarte-García A, Hiraki LT, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2025 Mar 24. doi: 10.1002/acr.25528Sammaritano LR, Askanase A, Bermas BL, Dall’Era M, Duarte-García A, Hiraki LT, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2025 Mar 24. doi: 10.1002/acr.25528Floris A, Chessa E, Sebastiani GD, Prevete I, Iannone F, Coladonato L, et al.; Study Group on Early SLE of the Italian Society of Rheumatology (SIR). Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: The real-world GULP prospective observational study. RMD Open. 2022;8(2):e002701. doi: 10.1136/rmdopen-2022-002701Floris A, Chessa E, Sebastiani GD, Prevete I, Iannone F, Coladonato L, et al.; Study Group on Early SLE of the Italian Society of Rheumatology (SIR). Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: The real-world GULP prospective observational study. RMD Open. 2022;8(2):e002701. doi: 10.1136/rmdopen-2022-002701Mathian A, Arnaud L, Ruiz-Irastorza G. Is it safe to withdraw low-dose glucocorticoids in SLE patients in remission? Autoimmun Rev. 2024;23(1):103446. doi: 10.1016/j.autrev.2023.103446Mathian A, Arnaud L, Ruiz-Irastorza G. Is it safe to withdraw low-dose glucocorticoids in SLE patients in remission? Autoimmun Rev. 2024;23(1):103446. doi: 10.1016/j.autrev.2023.103446Palmowski A, Pankow A, Terziyska K, Nielsen SM, Christensen R, Bliddal H, et al. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: A systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2024;64:152349. doi: 10.1016/j.semarthrit.2023.152349Palmowski A, Pankow A, Terziyska K, Nielsen SM, Christensen R, Bliddal H, et al. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: A systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2024;64:152349. doi: 10.1016/j.semarthrit.2023.152349Tselios K, Gladman DD, Su J, Urowitz MB. Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus. ACR Open Rheumatol. 2021;3(8):550-557. doi: 10.1002/acr2.11267Tselios K, Gladman DD, Su J, Urowitz MB. Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus. ACR Open Rheumatol. 2021;3(8):550-557. doi: 10.1002/acr2.11267Oiwa H, Suga T, Hosokawa Y, Araki K. Glucocorticoid-free remission in patients with SLE in the era of biologics: Immune complex disease is likely to benefit from current medications. Lupus. 2024;33(5):502-510. doi: 10.1177/09612033241238055Oiwa H, Suga T, Hosokawa Y, Araki K. Glucocorticoid-free remission in patients with SLE in the era of biologics: Immune complex disease is likely to benefit from current medications. Lupus. 2024;33(5):502-510. doi: 10.1177/09612033241238055Fasano S, Coscia MA, Pierro L, Ciccia F. Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study. Lupus. 2021;30(6):991-997. doi: 10.1177/09612033211002269Fasano S, Coscia MA, Pierro L, Ciccia F. Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study. Lupus. 2021;30(6):991-997. doi: 10.1177/09612033211002269Katsumata Y, Inoue E, Harigai M, Cho J, Louthrenoo W, Hoi A, et al.; Asia-Pacific Lupus Collaboration. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: A multinational observational cohort study. Ann Rheum Dis. 2024;83(8):998-1005. doi: 10.1136/ard-2023-225369Katsumata Y, Inoue E, Harigai M, Cho J, Louthrenoo W, Hoi A, et al.; Asia-Pacific Lupus Collaboration. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: A multinational observational cohort study. Ann Rheum Dis. 2024;83(8):998-1005. doi: 10.1136/ard-2023-225369Ji L, Gao D, Hao Y, Huang H, Wang Y, Deng X, et al. Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: A desirable and attainable goal. Rheumatology (Oxford). 2022;62(1):181-189. doi: 10.1093/rheumatology/keac225Ji L, Gao D, Hao Y, Huang H, Wang Y, Deng X, et al. Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: A desirable and attainable goal. Rheumatology (Oxford). 2022;62(1):181-189. doi: 10.1093/rheumatology/keac225Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Mitjavila F, Castro Salomó A, et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: A randomised clinical trial. Ann Rheum Dis. 2017;76(9):1575-1582. doi: 10.1136/annrheumdis-2016-210882Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Mitjavila F, Castro Salomó A, et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: A randomised clinical trial. Ann Rheum Dis. 2017;76(9):1575-1582. doi: 10.1136/annrheumdis-2016-210882Oon S, Huq M, Golder V, Ong PX, Morand EF, Nikpour M. Lupus low disease activity state (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis. 2019;78(5):629-633. doi: 10.1136/annrheumdis-2018-214427Oon S, Huq M, Golder V, Ong PX, Morand EF, Nikpour M. Lupus low disease activity state (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis. 2019;78(5):629-633. doi: 10.1136/annrheumdis-2018-214427Zen M, Saccon F, Gatto M, Montesso G, Larosa M, Benvenuti F, et al. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. Rheumatology (Oxford). 2020;59(7):1591-1598. doi: 10.1093/rheumatology/kez422Zen M, Saccon F, Gatto M, Montesso G, Larosa M, Benvenuti F, et al. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. Rheumatology (Oxford). 2020;59(7):1591-1598. doi: 10.1093/rheumatology/kez422Zen M, Fuzzi E, Loredo Martinez M, Depascale R, Fredi M, Gatto M, et al. Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. Rheumatology (Oxford). 2022;61(2):688-695. doi: 10.1093/rheumatology/keab373Zen M, Fuzzi E, Loredo Martinez M, Depascale R, Fredi M, Gatto M, et al. Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. Rheumatology (Oxford). 2022;61(2):688-695. doi: 10.1093/rheumatology/keab373Floris A, Piga M, Cauli A, Mathieu A. Predictors of flares in systemic lupus erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmun Rev. 2016;15(7):656-663. doi: 10.1016/j.autrev.2016.02.019Floris A, Piga M, Cauli A, Mathieu A. Predictors of flares in systemic lupus erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmun Rev. 2016;15(7):656-663. doi: 10.1016/j.autrev.2016.02.019Kostopoulou M, Ugarte-Gil MF, Pons-Estel B, van Vollenhoven RF, Bertsias G. The association between lupus serology and disease outcomes: A systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus. Lupus. 2022;31(3):307-318. doi: 10.1177/09612033221074580Kostopoulou M, Ugarte-Gil MF, Pons-Estel B, van Vollenhoven RF, Bertsias G. The association between lupus serology and disease outcomes: A systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus. Lupus. 2022;31(3):307-318. doi: 10.1177/09612033221074580Yeo AL, Kandane-Rathnayake R, Koelmeyer R, Golder V, Louthrenoo W, Chen YH, et al.; Asia Pacific Lupus Collaboration. SMART-SLE: Serology monitoring and repeat testing in systemic lupus erythematosus – An analysis of anti-double-stranded DNA monitoring. Rheumatology (Oxford). 2024;63(2):525-533. doi: 10.1093/rheumatology/kead231Yeo AL, Kandane-Rathnayake R, Koelmeyer R, Golder V, Louthrenoo W, Chen YH, et al.; Asia Pacific Lupus Collaboration. SMART-SLE: Serology monitoring and repeat testing in systemic lupus erythematosus – An analysis of anti-double-stranded DNA monitoring. Rheumatology (Oxford). 2024;63(2):525-533. doi: 10.1093/rheumatology/kead231

The authors declare that there are no conflicts of interest present.